(I) After treatment with IgG1 control and indicated DR5 agonists (KMTR2, Lexa, Tigatuzumab) ± ROCK1 inhibitors (GSK269962A, GSK429286A) tumor cells were co-cultured with anti-CD3 stimulated PD1+ effector Jurkat cells (stably expressing luciferase under NFAT-RE promoter). Relative luciferase signal was quantified and plotted after subtraction of background signal from untreated cells. 